Disease area
Hematologic malignancies
Multiple myeloma
B-cell malignancies
Myeloid malignancies
Classical hematology
Showing 12 recruiting clinical trials
Newly diagnosed MM – Maintenance
(following ASCT)
(following ASCT)
MajesTEC-4
Phase
NCT05243797
Compound
Teclistamab (BCMA × CD3 bispecific Ab) ± lenalidomide
Newly diagnosed MM (not candidate or not intended for ASCT ASCT)
MajesTEC-7
Phase
NCT05552222
Compound
Teclistamab (BCMA × CD3 bispecific Ab) or talquetamab (GPRC5D × CD3 bispecific Ab) + daratumumab (anti-CD38 mAb) + lenalidomide
Relapsed or refractory MM (≥3 prior LOT)
MonumenTAL-1
Phase
NCT04634552
Compound
Talquetamab (GPRC5D × CD3 bispecific Ab)
MM
Talisman
Phase
NCT06500884
Compound
Talquetamab (GPRC5D × CD3 bispecific Ab) + prophylaxis A/B/C/D or ramantamig (BCMA × GPRC5D × CD3 trispecific Ab)
Relapsed or refractory MM (≥3 prior LOT) or previously treated AL amyloidosis (≥1 prior LOT)
79635322MMY1001
Phase
NCT05652335
Compound
Ramantamig (BCMA × GPRC5D × CD3 trispecific Ab)
MM (1–3 prior LOT)
79635322MMY1002
Phase
b
NCT06768489
Compound
Ramantamig (JNJ-79635322; BCMA × GPRC5D × CD3 trispecific Ab) + daratumumab (anti-CD38 mAb) or pomalidomide or daratumumab + lenalidomide
MM (previously treated with cilta-cel in a clinical trial)
CARTinue
Phase
NCT05201781
Compound
No intervention (previously received cilta-cel [anti-BCMA CAR T-cell therapy])
MM
CARTITUDE-10
Phase
NCT07149857
Compound
Cilta-cel (anti-BCMA CAR T-cell therapy) + cyclophosphamide + induction therapy
Relapsed or refractory MM (≥3 prior LOT)
TRIlogy-3
Phase
NCT07266441
Compound
Ramantamig (JNJ-79635322; BCMA × GPRC5D × CD3 trispecific Ab)
Relapsed or refractory MM (≥3 prior LOT)
TRIlogy-4
Phase
NCT07258511
Compound
Ramantamig (JNJ-79635322; BCMA × GPRC5D × CD3 trispecific Ab) or teclistamab (BCMA × CD3 bispecific Ab)
Relapsed or refractory MM (1–3 prior LOT)
TRIlogy-5
Phase
NCT07518186
Compound
Ramantamig (JNJ-79635322; BCMA × GPRC5D × CD3 trispecific Ab) or teclistamab (BCMA × CD3 bispecific Ab)
Relapsed or refractory MM
TRI Pro*
Phase
NCT07589634
Compound
Ramantamig (JNJ-79635322; BCMA × GPRC5D × CD3 trispecific Ab) ± tocilizumab
The safety and efficacy of the investigational use of these products have not been determined.
There is no guarantee that the investigational uses listed will be filed with and/or approved for marketing by any regulatory agency. Teclistamab and talquetamab include technology licensed from Genmab A/S. Cilta-cel is developed in collaboration with Legend Biotech.
*Soon to be recruiting.
Ab, antibody; AL, amyloid light chain; ASCT, autologous stem cell transplant; BCMA, B-cell maturation antigen; CAR, chimeric antigen receptor; CD, cluster of differentiation; cilta-cel, ciltacabtagene autoleucel; GPRC5D, G protein-coupled receptor class C group 5 member D; LOT, lines of therapy; mAb, monoclonal antibody; MM, multiple myeloma.